ADMA Biologics

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906.
Company Growth (employees)
Ramsey, US
Size (employees)
92 (est)+28%
ADMA Biologics was founded in 2004 and is headquartered in Ramsey, US

Key People at ADMA Biologics

Bryant E. Fong

Bryant E. Fong

Dov Goldstein

Dov Goldstein

James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman

ADMA Biologics Office Locations

ADMA Biologics has an office in Ramsey
Ramsey, US (HQ)
465 Nj 17

ADMA Biologics Data and Metrics

ADMA Biologics Financial Metrics

ADMA Biologics's revenue was reported to be $10.7 m in FY, 2016 which is a 49% increase from the previous period.
$, USD

Revenue (FY, 2016)

10.7 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(19.5 m)

EBIT (FY, 2016)

(17.3 m)

Market capitalization (23-Jun-2017)

40.6 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

9.9 m
ADMA Biologics's current market capitalization is $40.6 m.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


3.1 m5.9 m7.2 m10.7 m

Revenue growth, %


Gross profit

1 m2.2 m2.9 m

Gross profit Margin, %


Operating expense total

18.1 m21.9 m22.7 m28 m


(15 m)(16 m)(15.5 m)(17.3 m)

EBIT margin, %


Interest expense

618.2 k1.3 m1.8 m2.2 m

Interest income

7.6 k14.2 k37.8 k50.3 k

Pre tax profit

(15.5 m)(17.4 m)(18 m)

Net Income

(15.5 m)(16.8 m)(18 m)(19.5 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


26.1 m17.2 m10.4 m9.9 m

Accounts Receivable

384 k924.5 k1 m


1.7 m1.7 m3.4 m5 m

Current Assets

31.1 m24.1 m21.3 m21.7 m

Total Assets

32 m27.2 m23.7 m23.7 m

Accounts Payable

2.7 m1.8 m2.1 m2.6 m

Current Liabilities

3.7 m4.2 m4.2 m11.2 m

Additional Paid-in Capital

74.2 m75.5 m88.2 m102.5 m

Retained Earnings

(52.6 m)(69.4 m)(87.4 m)(106.9 m)

Total Equity

21.6 m6 m821 k

Financial Leverage

1.5 x4.5 x28.9 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(15.5 m)(16.8 m)(18 m)(19.5 m)

Depreciation and Amortization

247.9 k469.8 k469.6 k

Accounts Receivable

(384 k)(540.5 k)(93.6 k)


1.7 m(39.7 k)(1.7 m)(1.6 m)

Accounts Payable

2.7 m(937.8 k)308.7 k476.8 k

Cash From Operating Activities

13.6 m(14.7 m)(15.4 m)(18.3 m)

Purchases of PP&E

(2.3 m)(26.1 k)(73.4 k)

Cash From Investing Activities

(4 m)(1.7 m)904.6 k

Cash From Financing Activities

9.8 m10.4 m16.8 m

Interest Paid

785.5 k1.3 m1.5 m

ADMA Biologics Market Value History

ADMA Biologics News and Updates

ADMA Biologics Company Life and Culture

You may also be interested in